跳至主要内容
临床试验/NCT01170975
NCT01170975已完成1 期

An Open-label, Single-dose, Randomized, Crossover Study to Determine the Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsule in Solid Tumor Cancer Subjects

Genta Incorporated1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
12
试验地点
1
主要终点
Pharmacokinetic parameters

研究概览

简要总结

This study explores the effects of food (a high-fat meal) on the pharmacokinetics of tesetaxel.

详细描述

This study is being conducted to determine whether the pharmacokinetics of a single dose of tesetaxel administered as a capsule is affected by co-administration with food (a high-fat meal).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Treatment sequence 1

Other

Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state

干预措施: Tesetaxel 10 mg with and then without food (Drug)

Treatment sequence 2

Other

Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state

干预措施: Tesetaxel 10 mg without and then with food (Drug)

结局指标

主要结局

Pharmacokinetic parameters

时间窗: Predose and postdosing up to 36 days after administration of each dose

Pharmacokinetic parameters include the area under the blood concentration-time curve (AUC0-inf, AUC0-t), concentration 24 h post dose (C24), maximum blood concentration (Cmax), time to maximum blood concentration (Tmax), terminal half-life (t½), and oral clearance (CL/F)

次要结局

  • Safety and tolerability(From screening through 36 days after administration of the final dose)

研究者

发起方
Genta Incorporated
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验